2025
18-OR: Lower Incretin Effect and Reduced GIP Characterize the Metabolic Phenotype of People with Multiple Islet Autoantibodies and Normal Glucose Tolerance
GALDERISI A, MARCHIORI H, ALGUARD M, DESOUSA M, TICHY E, FLYNN A, GAGLIA J, DALLA MAN C, SHERR J. 18-OR: Lower Incretin Effect and Reduced GIP Characterize the Metabolic Phenotype of People with Multiple Islet Autoantibodies and Normal Glucose Tolerance. Diabetes 2025, 74 DOI: 10.2337/db25-18-or.Peer-Reviewed Original ResearchOral glucose tolerance testNormal glucose toleranceInsulin secretion rateGlucose tolerance testIncretin effectStage 0GLP-1Islet autoantibodiesTolerance testGlucose tolerancePreclinical type 1 diabetesStage 1Reduced incretin effectHormone GLP-1Iv glucose tolerance testType 1 diabetesMultiple islet autoantibodiesPhenotype of peopleOral minimal modelC-peptideMetabolic phenotypeGlucose profilesIncretinMeasurement of glucoseInsulin secretion
2024
BOLSTERING SENSE OF PURPOSE FOR INDIVIDUALS LIVING WITH EARLY DEMENTIA: AN APPRECIATIVE INQUIRY APPROACH
Mroz E, Monin J, Keefe K, DeFrancesco E, Gil H. BOLSTERING SENSE OF PURPOSE FOR INDIVIDUALS LIVING WITH EARLY DEMENTIA: AN APPRECIATIVE INQUIRY APPROACH. Innovation In Aging 2024, 8: 105-105. PMCID: PMC11688711, DOI: 10.1093/geroni/igae098.0338.Peer-Reviewed Original ResearchSense of purposeLack of evidence-based practiceAppreciative inquiry methodCommunity-based interventionsCommunity-based resourcesEvidence-based practiceAppreciative inquiry approachLife-changing diagnosisAvailability of supportLifestyle courseADRDCommunity settingsEarly dementiaDiagnosis of Alzheimer's diseaseDesign thinking workshopDiminished sense of purposeInquiry methodDementiaDiminished senseStage 0InterventionAdultsTeamInquiry approachAlzheimer's diseaseSecond Primary Breast Cancer in Young Breast Cancer Survivors
Brantley K, Rosenberg S, Collins L, Ruddy K, Tamimi R, Schapira L, Borges V, Warner E, Come S, Zheng Y, Kirkner G, Snow C, Winer E, Partridge A. Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncology 2024, 10: 718-725. PMID: 38602683, PMCID: PMC11009864, DOI: 10.1001/jamaoncol.2024.0286.Peer-Reviewed Original ResearchGenetic testingYoung Women's Breast Cancer StudyYoung breast cancer survivorsBreast cancerBreast cancer survivorsYoung BC survivorsPrimary breast cancerGermline genetic testingIII BCMedical record reviewBreast Cancer StudyGermline pathogenic variantsPathogenic variantsBC survivorsTreatment decision-makingCancer survivorsFine-Gray subdistribution hazard modelCumulative incidencePV carriersSubdistribution hazard modelStage 0Patient surveyCharacterize risk factorsUnilateral mastectomyPrimary BC
2023
Modifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives
Fayanju O, Greenup R, Zafar S, Hyslop T, Hwang E, Fish L. Modifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives. Journal Of Surgical Research 2023, 284: 269-279. PMID: 36610386, PMCID: PMC10020986, DOI: 10.1016/j.jss.2022.11.074.Peer-Reviewed Original ResearchConceptsBreast cancer treatmentBreast cancerModifiable barriersCancer treatmentProvider perspectivesSurgical oncology careBreast cancer careAdvanced practice providersSingle health systemModifiable contributorOncologic careModifiable factorsOncology careCancer careTreatment receiptPatients' perceptionsStage 0Practice providersCare receiptPatientsExemplar quotesThematic analysisSuboptimal communicationHealth systemTreatment costs
2022
Occupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study
Ryan SM, Mroz MM, Herzog EL, Ryu C, Fingerlin TE, Maier LA, Gulati M. Occupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study. Respiratory Medicine 2022, 200: 106923. PMID: 35932543, DOI: 10.1016/j.rmed.2022.106923.Peer-Reviewed Original ResearchConceptsAlpha-1 antitrypsin deficiencyCardiac sarcoidosisSarcoidosis StudyAntitrypsin deficiencyRadiation exposureNon-cardiac sarcoidosisNon-chronic diseasesMultiple comparisonsEnvironmental exposure dataExtrapulmonary diseasePulmonary involvementGranulomatous disorderSarcoidosis phenotypesRisk factorsSpecific disease phenotypesStage 0Number of exposuresSarcoidosisExposure assessment toolsSusceptible individualsSpecific exposuresDiseaseEnvironmental exposuresExposure dataIndividual exposure
2020
The effect of body mass index (BMI) on survival in patients with breast cancer and obesity-associated conditions.
Caddell K, Ren Y, Sampathkumar A, Almond C, Ladipo O, Champ C, Rosenberger L, Greenup R, Plichta J, DiLalla G, Menendez C, Tolnitch L, Hwang E, Hyslop T, Fayanju O. The effect of body mass index (BMI) on survival in patients with breast cancer and obesity-associated conditions. Journal Of Clinical Oncology 2020, 38: 203-203. DOI: 10.1200/jco.2020.38.29_suppl.203.Peer-Reviewed Original ResearchBody mass indexObesity-associated conditionsUnadjusted overall survivalClass 1 obesityOverall survivalBreast cancer outcomesBreast cancerWorse OSObese patientsOverweight womenMass indexBMI classesCancer outcomesAssociation of BMIEffect of BMINon-Hispanic black womenKaplan-Meier methodNormal-weight womenDiagnosis of obesityProportional hazards modelBreast cancer diagnosisStage 0Hazards modelHypertensionObesitySensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins LC, Miller KD, Blumenstiel B, Trippa L, Cibulskis C, Neuberg DS, DeFelice M, Freeman SS, Lennon NJ, Wagle N, Ha G, Stover DG, Choudhury AD, Getz G, Winer EP, Meyerson M, Lin NU, Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson VA. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research 2020, 26: 2556-2564. PMID: 32170028, PMCID: PMC7654718, DOI: 10.1158/1078-0432.ccr-19-3005.Peer-Reviewed Original ResearchConceptsMinimal residual diseaseMetastatic breast cancerDigital droplet PCRBreast cancerTumor mutationsResidual diseaseMRD detectionEarly-stage breast cancerCurative-intent treatmentCohort of patientsEarly-stage diseaseMedian lead timeClinical data collectionWhole-exome sequencingMRD testFirst positive sampleDistant recurrenceMost patientsMetastatic diagnosisStage 0PatientsPlasma samplingClinical sensitivityPatient-specific mutationsCfDNA samples
2019
Resection of Cavity Shave Margins in Stage 0–III Breast Cancer Patients Undergoing Breast Conserving Surgery
Dupont E, Tsangaris T, Garcia-Cantu C, Howard-McNatt M, Chiba A, Berger AC, Levine EA, Gass JS, Gallagher K, Lum SS, Martinez RD, Willis AI, Pandya SV, Brown EA, Fenton A, Mendiola A, Murray M, Solomon NL, Senthil M, Ollila DW, Edmonson D, Lazar M, Namm JP, Li F, Butler M, McGowan NE, Herrera ME, Avitan YP, Yoder B, Walters LL, McPartland T, Chagpar AB. Resection of Cavity Shave Margins in Stage 0–III Breast Cancer Patients Undergoing Breast Conserving Surgery. Annals Of Surgery 2019, 273: 876-881. PMID: 31290763, DOI: 10.1097/sla.0000000000003449.Peer-Reviewed Original ResearchConceptsCavity shave marginsBreast cancer patientsPartial mastectomyPositive marginsRe-excision ratesCancer patientsShave marginsStage 0Standard partial mastectomyMedian patient ageSingle-center studyBreast conserving surgeryPrimary outcome measurePositive margin rateConserving surgeryPatient ageClinicopathologic factorsMargin clearanceMargin rateInclusion criteriaOutcome measuresPatientsResectionPractice settingsMastectomyIs Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database
Chowdhary M, Lee A, Gao S, Wang D, Barry PN, Diaz R, Bagadiya NR, Park HS, Yu JB, Wilson LD, Moran MS, Higgins SA, Knowlton CA, Patel KR. Is Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. Frontiers In Oncology 2019, 8: 678. PMID: 30693271, PMCID: PMC6339938, DOI: 10.3389/fonc.2018.00678.Peer-Reviewed Original ResearchLymph node irradiationNational Cancer DatabaseOverall survivalMultivariable analysisBreast cancerCancer DatabaseProton radiotherapyNon-metastatic breast cancerCox proportional hazards modelHigher heart dosesN2-N3 diseaseMultivariate logistic analysisProportional hazards modelAcademic facilitiesLogistic regression modelsHeart dosesAdjuvant radiotherapyNode irradiationHazard ratioNode positivityClinical benefitClinical trialsPRT patientsStage 0Hazards model
2018
Surgeon peer network characteristics and adoption of new imaging techniques in breast cancer: A study of perioperative MRI
Tannenbaum SS, Soulos PR, Herrin J, Pollack CE, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang S, Gross CP. Surgeon peer network characteristics and adoption of new imaging techniques in breast cancer: A study of perioperative MRI. Cancer Medicine 2018, 7: 5901-5909. PMID: 30444005, PMCID: PMC6308117, DOI: 10.1002/cam4.1821.Peer-Reviewed Original ResearchConceptsPrimary care physiciansPatient-sharing networksBreast cancerPerioperative MRISubsequent receiptNon-cancer patientsBreast cancer practiceMultivariable hierarchical modelsUse of MRIClinical characteristicsCare physiciansFemale patientsCancer practiceMedicare databaseNew imaging techniquesMedicare sampleStage 0Claims dataPatientsPhysician groupsMRISurgeonsCancerEquivocal evidencePhysiciansRandomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study
Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu L, Li FY, Zhou Y, Chagpar A, Ferrucci LM, Pusztai L, Irwin ML. Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Breast Cancer Research And Treatment 2018, 172: 105-112. PMID: 30062572, DOI: 10.1007/s10549-018-4895-7.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsWeight loss interventionUsual care groupBody mass indexBreast cancer riskCancer survivorsUsual careLoss interventionBreast cancerStage 0Quantitative polymerase chain reactionCare groupTelomere lengthCancer riskStage II/III breast cancerObese breast cancer survivorsWeight lossI breast cancerNon-Hispanic whitesPurposeSome studiesMass indexIntervention groupPhysical activityBlood samplesConclusionOur findingsThe impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment.
Matutino A, Lewis J, Verma S, Taylor A, Huber S, Chen G. The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment. Journal Of Clinical Oncology 2018, 36: 67-67. DOI: 10.1200/jco.2018.36.7_suppl.67.Peer-Reviewed Original ResearchBreast cancerDifferent age groupsCurative treatmentAge groupsRetrospective cross-sectional analysisAnti-hormonal therapyBreast conserving surgeryCancer Patient QuestionnaireQuality of lifeImpact of ageCross-sectional analysisHigh financial burdenSurvivorship careConserving surgeryPatient questionnaireCurative therapySecond cancersLess painQOL scoresInvasive diseaseQoL dataHigh prevalenceStage 0Radiation therapyOngoing anxietyThe Effect of Hospital Volume on Breast Cancer Mortality
Greenup R, Obeng-Gyasi S, Thomas S, Houck K, Lane W, Blitzblau R, Hyslop T, Hwang E. The Effect of Hospital Volume on Breast Cancer Mortality. Annals Of Surgery 2018, 267: 375-381. PMID: 27893532, PMCID: PMC5994238, DOI: 10.1097/sla.0000000000002095.Peer-Reviewed Original ResearchConceptsHigh-volume centersNational Cancer Data BaseHospital volumeVolume centersBreast cancerHazard ratioImproved survivalStage 0Case volumeMultivariable Cox proportional hazards modelsMultidisciplinary breast cancer treatmentMultivariable Cox proportional hazardsSurgeons National Cancer Data BaseCox proportional hazards modelAnnual hospital volumeLess common cancersUnilateral breast cancerBreast cancer mortalityBreast cancer patientsCubic spline analysisLog-rank testBreast cancer treatmentCox proportional hazardsProportional hazards modelHigher case volume
2017
Impact of insurance status on treatment for stage 0-IV breast cancer.
Greenup R, Thomas S, Fayanju O, Hyslop T, Hwang E. Impact of insurance status on treatment for stage 0-IV breast cancer. Journal Of Clinical Oncology 2017, 35: 6532-6532. DOI: 10.1200/jco.2017.35.15_suppl.6532.Peer-Reviewed Original ResearchRisk of deathInsurance statusBreast cancerStage 0Private insuranceMultivariate Cox proportional hazards modelStage 1 breast cancerUninsured breast cancer patientsNational Cancer Data BaseCox proportional hazards modelUnilateral stage 0Receipt of chemotherapyReceipt of surgeryStage 4 diseaseReceipt of treatmentBreast cancer patientsProportional hazards modelBinary logistic regressionNeoadjuvant chemotherapyOncologic outcomesOverall survivalBilateral mastectomyMedian ageUninsured womenTreatment patternsEconomic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals Of Surgery 2017, 265: 39-44. PMID: 27192352, PMCID: PMC5605915, DOI: 10.1097/sla.0000000000001799.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularConnecticutFemaleFollow-Up StudiesHealth ExpendituresHospital CostsHumansMargins of ExcisionMastectomy, SegmentalMiddle AgedProspective StudiesReoperationSingle-Blind MethodTreatment OutcomeConceptsCavity shave marginsStandard partial mastectomyPartial mastectomyRe-excision ratesIndex surgeryInitial surgeryBreast cancerHospital perspectiveLower re-excision ratesDirect hospital costsBreast cancer patientsOperating room timeReoperative surgeryBaseline characteristicsOperative timePositive marginsShave marginsCancer patientsHospital costsStage 0Room timeSurgeryPathology costsPatientsMastectomy
2015
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer
Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. New England Journal Of Medicine 2015, 373: 503-510. PMID: 26028131, PMCID: PMC5584380, DOI: 10.1056/nejmoa1504473.Peer-Reviewed Original ResearchConceptsCavity shave marginsPositive marginsPartial mastectomyShave marginsDuctal carcinomaBreast cancerInvasive cancerOutcome measuresStandard partial mastectomySecondary outcome measuresPrimary outcome measureLower ratesRoutine resectionMedian ageClinicopathological characteristicsCavity shavingMargin clearanceSecond surgeryInvasive carcinomaStage 0MastectomyPathological testingPatientsFurther diseaseVolume of tissue
2014
A phase II trial of balloon-catheter partial breast brachytherapy optimization in the treatment of stage 0, I, and IIA breast carcinoma
Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB. A phase II trial of balloon-catheter partial breast brachytherapy optimization in the treatment of stage 0, I, and IIA breast carcinoma. Journal Of Radiation Oncology 2014, 3: 371-378. PMID: 25485042, PMCID: PMC4254816, DOI: 10.1007/s13566-014-0153-8.Peer-Reviewed Original ResearchSuperior PTV coverageSkin toxicityPTV coverageStage 0Single-arm phase II studyAcute grade 2 toxicityGrade 2 skin toxicityCommon acute toxicitiesGrade 1 erythemaGrade 1 fibrosisGrade 2 toxicityPhase II studyPhase II trialPartial breast irradiationBalloon catheter brachytherapyLower skin dosesOverall low rateMedian V90II trialPrimary endpointII studyAdditional patientsTreatment eligibilityBreast irradiationBrachytherapy results
2013
SHAVE: A randomized controlled trial of routine shave margins versus standard partial mastectomy.
Chagpar A, Stavris K, Killelea B, Tsangaris T, Horowitz N. SHAVE: A randomized controlled trial of routine shave margins versus standard partial mastectomy. Journal Of Clinical Oncology 2013, 31: tps1145-tps1145. DOI: 10.1200/jco.2013.31.15_suppl.tps1145.Peer-Reviewed Original ResearchStandard partial mastectomyPositive margin ratePartial mastectomyRe-excision ratesShave marginsCosmetic outcomeMargin rateBreast cancerVolume of tissueCavity shave marginsNeoadjuvant chemotherapyPrimary endpointMastectomy groupLocal recurrenceOperative timeOutcome measuresStage 0Intraoperative timeMargin groupMost seriesPatientsMastectomyInformed consentAdditional tissueOperating roomQuality of life and symptoms in male breast cancer survivors
Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow S, Winer EP, Partridge AH. Quality of life and symptoms in male breast cancer survivors. The Breast 2013, 22: 197-199. PMID: 23313328, DOI: 10.1016/j.breast.2012.12.014.Peer-Reviewed Original ResearchConceptsMale breast cancer survivorsBreast cancer survivorsQuality of lifeCancer survivorsProstate Cancer Index CompositeCancer Therapy-BreastFACT-B scoresHormonal scoresHormonal symptomsSymptom burdenBreast cancerStage 0Depression ScaleFunctional assessmentHospitalized AnxietyMale survivorsSymptomsSurvivorsSexual scaleOverall qualityScoresPatientsCancer
2012
A Prospective, Multicenter Study of Complementary/Alternative Medicine (CAM) Utilization During Definitive Radiation for Breast Cancer
Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S. A Prospective, Multicenter Study of Complementary/Alternative Medicine (CAM) Utilization During Definitive Radiation for Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2012, 85: 40-46. PMID: 22658441, DOI: 10.1016/j.ijrobp.2012.03.025.Peer-Reviewed Original ResearchConceptsBreast cancer patientsAlternative medicine utilizationCancer patientsBreast cancerCAM practicesDefinitive radiationCAM usersMedicine utilizationBreast patientsFirst prospective studyRadiation therapy useMulti-institutional studyOral CAMYounger patientsTherapy useCAM useStudy cohortCAM usageMulticenter studyProspective studyCAM utilizationStage 0Radiation therapyPatientsMultivariate analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply